The Shkreli Pill
The only pill worth swallowing. Markets, memes, medicine, and mayhem — served straight, no chaser. Watch the video versions on YouTube : https://www.youtube.com/@TheShkreliPill/videos.
Episodes
In this episode, Martin explains why he believes increasing Chinese semiconductor supply could create significant pressure for Micron and the broader memory market. He outlines his bearish outlook on semiconductor stocks, examining supply growth, memory pricing, capital spending, and industry cycles, before discussing ASML and Micron (MU) and the risks and catalysts shaping his current short theses.
In this episode, Martin discusses how investors can evaluate buying opportunities during sharp market selloffs and determine when fear may have pushed prices below underlying value. He shares lessons on valuation, market psychology, position sizing, and managing risk when trading against panic, before analyzing Liquidia and examining its clinical prospects, competitive position, catalysts, valuation, and the risks shaping his inves...
In this episode, Martin examines Cerebras and whether its AI chip architecture could challenge Nvidia’s dominance in accelerated computing. He also lays out his bullish thesis on MongoDB and discusses the factors that could support a $400 valuation target, before turning to Ginkgo Bioworks and explaining his bearish outlook on the company, including its business model, financial performance, valuation, and investment risks.
In this episode, Martin reflects on a major loss from his short position in Kodiak Sciences and examines how a short squeeze moved the trade against him. He discusses position sizing, risk management, conviction, and the lessons he draws from losing millions on the position before turning to Nvidia, where he explores ways investors can search for alpha by analyzing expectations, valuation, AI demand, and potential market inefficien...
In this episode, Martin reflects on a costly short position in Kodiak Sciences and examines what went wrong with the trade, including the risks of conviction, timing, and unexpected catalysts. He also discusses the possibility of OpenAI eventually going public and what such a move could mean for investors, before explaining why he believes many financial models fail to capture reality and how assumptions, probabilities, and changin...
In this episode, Martin examines Meta’s relationship with Scale AI and discusses how the company could use its investment and Scale AI’s valuation to strengthen its position in the artificial intelligence race. He also questions Intel’s characterization of demand and examines the underlying semiconductor-market dynamics before revisiting Moderna, discussing its pipeline, valuation, catalysts, and the risks shaping...
In this episode, Martin lays out his bearish thesis on Kodiak Sciences and explains the factors driving his cautious outlook on the biotech company. He examines its clinical pipeline, trial data, competitive landscape, regulatory considerations, and valuation, discussing the risks and catalysts he believes investors should consider when evaluating the stock.
In this episode, Martin discusses a biotech company he believes faces significant regulatory risk from an upcoming FDA decision and examines the clinical and valuation factors behind his bearish outlook. He also analyzes Dell’s exposure to AI infrastructure and explains why its low-margin business model could limit the upside, before sharing his perspective on index investing, market valuations, and why he believes selective ...
In this episode, Martin outlines his bearish thesis on AMD and examines what he believes is an overlooked weakness in the company’s position within the AI computing market. He also discusses Broadcom’s role in developing custom AI accelerators for Google and explores the implications of a major Oracle deal, focusing on AI infrastructure economics, competitive dynamics, capital spending, and the valuations shaping his ou...
In this episode, Martin discusses why GPUs have gained a major advantage over traditional CPUs for artificial intelligence workloads and examines Nvidia’s position within the rapidly expanding AI computing market. He also breaks down a mathematical assumption he believes is contributing to excessive technology valuations, exploring AI infrastructure economics, capital spending, expected returns, and whether current market exp...
In this episode, Martin discusses a sharp move in Moderna and examines the market dynamics behind what he describes as a major short squeeze. He also breaks down the declines in SanDisk and Micron, exploring memory pricing, semiconductor-cycle expectations, supply and demand, valuation, and changing investor sentiment while explaining the factors shaping his outlook on the memory sector.
In this episode, Martin explains why he remains skeptical of the investment case for quantum computing and outlines the reasoning behind his bearish outlook on the sector. He discusses technological limitations, commercialization timelines, competitive dynamics, valuations, and investor expectations, examining whether current quantum computing stocks adequately reflect the risks and uncertainty surrounding the industry’s long...
In this episode, Martin discusses why he believes Nidec is positioned to benefit from the continued expansion of AI infrastructure and data centers. He also explains his decision to reduce exposure to technology stocks in favor of AbbVie, examining the pharmaceutical company’s valuation and growth outlook, before analyzing Lam Research (LRCX) and the opportunities and risks surrounding semiconductor equipment demand and the b...
In this episode, Martin explains why he is taking bearish positions in semiconductor stocks and examines what he believes is changing beneath the surface of the industry. He discusses AI-driven demand, valuations, capital spending, supply dynamics, and the semiconductor cycle before analyzing Spyre Therapeutics (SYRE) and Intel, outlining the catalysts, risks, and factors shaping his current investment outlook on both companies.
In this episode, Martin lays out his bearish thesis on AMD and explains why he believes expectations surrounding AI growth have pushed its valuation to unsustainable levels. He also discusses the outlook for Ozempic and the increasingly competitive GLP-1 drug market, analyzing Novo Nordisk’s pipeline, market position, valuation, and the risks he believes could challenge its future growth.
In this episode, Martin discusses the information gap between institutional and retail investors, examining how access to specialized datasets, research tools, and market intelligence can create advantages on Wall Street. He also explores effective altruism in Silicon Valley, discussing its ideas, influence, and the incentives surrounding the movement while sharing his perspective on how wealth, technology, and philanthropy interse...
In this episode, Martin breaks down his current short positions and explains the reasoning behind his bearish trades. He discusses his concerns about QCLS and the company’s development since its launch, then analyzes Nebius and Abivax, examining their businesses, valuations, catalysts, competitive positions, and the risks shaping his current investment outlook on each stock.
In this episode, Martin brings one of his top traders onto the stream for a discussion about markets, investing, and developing an edge. They explore trade selection, position sizing, risk management, and the research process behind identifying opportunities, while sharing lessons on trading psychology, discipline, and what separates consistently strong decision-making from ordinary market speculation.
In this episode, Martin discusses his decision to leave Q/C Technologies and explains his concerns about the company’s approach to financial engineering. He reflects on disagreements over capital allocation, financing, and corporate strategy, while sharing his perspective on the financial consequences of stepping away and the broader lessons investors and founders can draw from conflicts over how a company is managed.
In this episode, Martin reflects on leaving one of his companies and discusses the financial consequences of that decision, along with the lessons he took from the experience. He also explains why he believes Ultragenyx is significantly undervalued and analyzes QCLS, examining each company’s pipeline, valuation, catalysts, and the risks shaping his current investment outlook.
Popular Podcasts
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by Audiochuck Media Company.
DISGRACELAND is an award-winning music and true crime podcast about musicians getting away with murder and behaving very badly. Jerry Lee Lewis's 5th wife? Dead. Sid and Nancy? Both dead. Why? Because musicians are insane, and insane things happen to them. Why did we lose Amy Winehouse at 27? Was Debbie Harry really abducted by Ted Bundy as she claims? Is Patti Smith not just the "Godmother of Punk", but also the "Original True Crime Girl"? What really happened the night of the Jay Z nightclub stabbing? What do the Diddy indictments truly reveal? All these stories and more, on artists from every genre and their true crimes, in our massive 260-plus story archive. The Dead, the Stones, Johnny, Willie, Frank, Kurt, Courtney, Gaga, Lana, Taylor, and too many to name. DISGRACELAND is music history come to life through audio storytelling as you've never heard it before, with revealing facts: yes, assassins are the real reason the Beatles quit touring—reclaimed myths: no, Mama Cass didn't die from choking on a ham sandwich––and constant reckoning between art and artist––all told through the lens of true crime. This is the podcast for the self-proclaimed "Disgos", the musically obsessed and the true crime heads; the outsiders, the independent thinkers who know that the best history is the history that gets buried. DISGRACELAND is where host Jake Brennan tells the stories they didn't want told. The kind you'll end up telling someone else. Get ready to uncover hidden truths and buckle up for truly edge-of-your-seat storytelling. New, fully scripted, sound-designed episodes are released every Tuesday. Bonus chat-style episodes where Jake responds to voicemails, texts, and emails from Disgos hit on Thursdays, and "Rewind" episodes from our archive drop on Sundays. DISGRACELAND is not a journalistic podcast. It's an entertainment podcast inspired by true events. Certain dialogue and scenes are dramatized, as is common in scripted entertainment based on real stories. Sources and credits for each episode are available at www.disgracelandpod.com. To unlock ad-free listening, exclusive content, and connect with your fellow Disgos, go to www.disgracelandpod.com to become an All Access member. Rocka Rolla.